New creatine study will track adherence in postmenopausal women

Key Takeaways

• The ATENEA study is designed to measure adherence to a creatine-based supplement over 12 weeks in estrogen-depleted adult women.
• Its primary outcomes are percentage of doses consumed and the share of participants reaching at least 80% adherence.
• Secondary measures include persistence, satisfaction, tolerability, and adherence to recommended physical activity.
• Strength, body composition, quality of life, joint pain, and skin health are exploratory outcomes, so the study is not primarily testing effectiveness.
• Because this is an observational routine-practice study, it may show how creatine is used in the real world, but it cannot establish cause and effect.

What this study is actually testing

The key news here is straightforward: the ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women has been registered on ClinicalTrials.gov to track whether adult women in an estrogen-depleted state can realistically stick with a creatine-based supplement over 12 weeks in everyday clinical practice.

That distinction matters. This is not primarily a performance trial and it is not, based on the available registry entry, a study designed to prove that creatine improves strength, body composition, skin, or joint symptoms in this group. Instead, its main purpose is to describe adherence: how many prescribed doses participants actually take, and what proportion reach a threshold of at least 80% adherence.

The supplement named in the registry is Creaticare FEM. Beyond dose-taking, the study will also assess persistence, satisfaction, tolerability, and adherence to recommended physical activity. A set of outcomes that many readers will care about most, including muscle strength, body composition, quality of life, joint pain, and skin health, are listed only as exploratory outcomes.

For readers considering supplementation, that means the study could still be useful. One of the most practical questions in sports nutrition is not just whether something can work under ideal conditions, but whether people actually continue taking it. A real-world adherence study can help answer that question, especially in a group frequently discussed in relation to muscle and healthy ageing. For practical basics, our creatine guides and creatine dosage calculator cover the standard evidence-based approaches.

How the ATENEA study is designed

According to the ClinicalTrials.gov entry, ATENEA is a prospective, multicenter, observational clinical study conducted under routine clinical practice conditions. In plain language, that means researchers plan to follow participants forward in time across more than one site, while observing what happens in a real-world care setting rather than tightly controlling every variable in a classic randomised trial.

The target population is estrogen-depleted adult women. The registry summary does not provide the level of detail a full paper would, so readers should be careful not to infer more than is there. “Estrogen-depleted” often points toward peri- or postmenopausal status or similar hormonal contexts, but the exact inclusion criteria, baseline characteristics, supplement protocol details, and eventual sample size reporting are not available in the brief abstract supplied here.

The primary adherence outcomes are clearly defined:

• Percentage of doses consumed
• Proportion of participants achieving at least 80% adherence

Secondary outcomes include persistence, satisfaction, tolerability, and adherence to recommended physical activity. Exploratory outcomes include muscle strength, body composition, quality of life, joint pain, and skin health.

This design has one clear strength: it should reflect what supplement use looks like outside an idealised lab setting. But it also comes with obvious limits. Without randomisation and a control group, an observational study is not built to isolate the effects of creatine from the effects of training, expectations, changes in diet, symptom fluctuation, or the simple fact that people who adhere well may differ from people who do not.

Why adherence matters for creatine in midlife and older women

Adherence sounds less exciting than a headline-grabbing strength result, but for creatine it may be one of the most practical issues in the field. Creatine only makes sense as a supplement if people take it consistently enough to maintain elevated muscle creatine stores over time. If adherence is poor, even a well-supported ingredient can underperform in the real world.

This is especially relevant in estrogen-depleted women, a group often discussed in relation to changes in muscle mass, strength, function, and quality of life with ageing. The broader creatine literature has long focused on sport and resistance training, but interest has expanded into healthy ageing and female-specific use cases. That does not mean every subgroup responds the same way, or that every marketed formula is equally well supported. It means consistency and tolerability become central practical questions.

Mainstream evidence still supports creatine monohydrate as the most-studied form. Common protocols are either:

• Loading: about 20 g/day split into 4 doses for 5-7 days, then maintenance
• Maintenance only: about 3-5 g/day

Whether a particular product uses a simple once-daily approach or a more complex regimen can affect adherence. So can taste, gastrointestinal comfort, price, routine fit, and whether users are also trying to follow an exercise plan. That is why a study like this can matter even before any efficacy claims are tested rigorously.

Readers comparing options should focus first on the basics: ingredient transparency, sensible dosing, and evidence-based forms. Our best creatine rankings, creatine brand reviews, and creatine product catalog can help you sort through the market without confusing marketing with evidence.

What readers should not assume from this registry entry

The biggest risk with an early study listing like this is overreading it. At this stage, the source is a ClinicalTrials.gov registry entry and brief summary, not a peer-reviewed results paper. So there are several things readers should not assume.

• Do not assume the study has already shown benefit. The supplied source material describes objectives, not results.
• Do not assume exploratory outcomes will improve. Strength, body composition, quality of life, joint pain, and skin health are being explored, not established.
• Do not assume any effect, if later seen, was caused by creatine alone. This is observational research in routine practice.
• Do not assume the findings will automatically generalise to all women. The population is specifically estrogen-depleted adult women.

It is also worth noting that the product in question is a named commercial supplement, not merely generic creatine monohydrate as a standalone ingredient. That does not invalidate the study, but it does mean readers should separate evidence about creatine as a nutrient from evidence about one branded formulation used in one study design.

For broader context, the most established consensus documents on creatine still point to creatine monohydrate as effective and generally well supported when used appropriately, especially in exercise contexts. The ISSN position stand and a later review on common questions and misconceptions about creatine are useful references here.

In other words: this registry entry is interesting, but it is a starting point, not a verdict.

How this fits the broader creatine evidence base

The broader creatine story is already much larger than this one study. Across the existing literature, creatine is among the most studied sports nutrition supplements, with the strongest evidence historically centred on high-intensity exercise performance, lean mass support in training contexts, and the safety and efficacy of creatine monohydrate when used appropriately.

What ATENEA adds, if completed and reported well, is not likely to be a revolution in mechanism. Its potential contribution is more practical: whether women in an estrogen-depleted state actually take a creatine-based supplement consistently in routine care, whether they tolerate it, and whether they remain satisfied enough to continue. Those are underappreciated questions because efficacy means little without follow-through.

That said, this study also points toward a growing area of interest: creatine beyond young male athletes. Research and commentary increasingly examine older adults, women, and non-sport outcomes. Some of those areas are promising, but the evidence base is less uniform and often more conditional on exercise, baseline status, study design, and the specific endpoints measured.

A sensible interpretation is that ATENEA may help fill a real-world evidence gap rather than settle the bigger debate. If future publications show strong adherence and acceptable tolerability, that would support the feasibility of using creatine-based supplementation in this population. If exploratory outcomes also move in a favourable direction, that would be hypothesis-generating, not definitive proof on its own.

For readers, the practical hierarchy remains the same: choose evidence-based forms, use sensible dosing, pair supplementation with training when appropriate, and avoid overinterpreting early-stage study registrations.

Bottom line for people considering creatine

The immediate takeaway is simple: ATENEA is a new real-world study of whether estrogen-depleted women can stick with a creatine-based supplement for 12 weeks, with adherence as the main outcome. It does not yet show that the supplement improves strength, body composition, skin, joints, or quality of life.

Still, the study is worth watching because adherence is a real barrier in supplementation. If a product is hard to tolerate, inconvenient to take, or difficult to sustain alongside exercise advice, that matters just as much as its theoretical benefits.

If you are considering creatine now, the practical evidence has not changed because of this registry entry. For most healthy adults using creatine for exercise-related goals, creatine monohydrate remains the standard choice, typically at 3-5 g/day without needing anything more elaborate. A loading phase of about 20 g/day split into 4 doses for 5-7 days can saturate stores faster, but it is optional.

Who should pay special attention to upcoming ATENEA results? Women in peri- or postmenopausal contexts, clinicians interested in routine-practice adherence, and anyone trying to separate lab efficacy from real-world usability.

The bottom line: this is a useful study question, not a breakthrough result. Watch for the final data, read any eventual publication carefully, and keep your expectations tied to what the study is actually designed to show.

ATENEA study at a glance

• 12 weeks Supplement period — Participants will receive the creatine-based supplement for 12 weeks.
• ≥80% Adherence threshold — One primary outcome is the proportion of participants who achieve at least 80% adherence.
• 3-5 g/day Typical maintenance dose — Mainstream creatine monohydrate maintenance dosing in the broader evidence base.
• 20 g/day Typical loading protocol — Often split into 4 doses for 5-7 days to saturate stores faster.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN